Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Overview
Date Founded

2014

Headquarters

60 Jubilee Avenue,Milton Park,Abingdon, Oxfordshire OX14 4RX

Type of Company

Public

Employees (Worldwide)

400

Industries

Biotechnology

Company Description

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Adaptimmune Therapeutics PLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Business Officer

Chief Patient Supply Officer

Senior Vice President & Chief Medical Officer

Vice President & Head, BioMarker Research & Development

Head, Autoimmune Group

Head of Process Development

Senior Director, Investor Relations

Paths to Adaptimmune Therapeutics PLC
Potential Connections via
Relationship Science
You
Adaptimmune Therapeutics PLC
Owners & Shareholders
Details Hidden

MCM’s strategy is to achieve this goal through maintaining a concentrated portfolio of long and short investments, over the long term, driven by differentiating research into company fundamentals. Their process includes three key aspects: definition, initiation and allocation. The firm invests primarily in equity securities, typically in the form of common stocks but investments may also include preferred stocks, convertible securities, warrants, stock purchase rights, depositary receipts, shares of investment companies and other equity-related interests. MCM’s research team delves into a company’s fundamentals and performs a “bottom-up” analysis to assess the intrinsic value, at the same time identifying any discrepancies between what the market thinks about a company’s future trajectory and the firm’s alternative view of that trajectory. They may employ active portfolio management strategies both as a hedge against volatility and to produce additional income and capital appreciation.

Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Recent Transactions
Details Hidden

Adaptimmune Therapeutics PLC issued . USD American Depositary Shares

Details Hidden

Adaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Transaction Advisors
Underwriter

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Underwriter

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Auditor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares (ADS)

Underwriter

Advised onAdaptimmune Therapeutics PLC issued . USD American Depositary Shares

Clients

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Key Stats and Financials As of 2019
Market Capitalization
$1.26B
Total Enterprise Value
$61.9M
Earnings Per Share
$-1.31
Revenue
$1.13M
Net Profit
$-138M
EBITDA
$-146M
EBITDAMargin
-13K%
Total Debt
$25.5M
Total Equity
$124M
Enterprise Value / Sales
54.92x
TEVNet Income
-0.45x
Debt TEV
0.41x
Three Year Compounded Annual Growth Rate Of Revenue
-56.99%
Five Year Compounded Annual Growth Rate Of Revenue
14.16%
Investors
Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

AVCAP aims to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries with a focus on publicly traded, and late-stage private biotechnology companies.

Details Hidden

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.

Suppliers
Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

BioLife Solutions Inc. Industrial Machinery & Manufacturing | Bothell, Washington

BioLife Solutions, Inc. engages in the development, manufacture and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Liberty Property Trust Real Estate Investment Trusts | Malvern, PA

Liberty Property Trust (NYSE:LRY) is a $6.9 billion real estate investment trust which owns 77.8 million square feet of office and industrial space in more than 21 markets throughout the United States and the United Kingdom (as of Sep. 30, 2012). Founded in 1972 and headquartered outside of Philadelphia, Liberty develops, acquires, leases and manages properties with the mission to enhance people's lives through extraordinary work environments. As an extension of this promise, Liberty is one of the nation's leading developers of high-performance green buildings. Liberty's more than 700 office and industrial properties offer exceptional locations, flexible design, thoughtful amenities, cost efficient operations and state-of-the-art technology to the company's 2,300 tenants. Liberty continuously increases the value of its portfolio through expert management, marketing and development

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adaptimmune Therapeutics PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adaptimmune Therapeutics PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Adaptimmune Therapeutics PLC.